Drug depots for treatment of pain and inflammation in sinus and nasal cavaties

Abstract

Effective treatments of pain and/or inflammation are provided. Through the administration of a biodegradable drug depot film, patch, strip or sponge being implantable at or near a cardiac tissue or within a nasal or sinus cavity, one can reduce, prevent or treat pain and/or inflammation.

1 - 11 . (canceled) 
     
     
         12 . A method of treating, reducing or preventing pain or inflammation in a patient in need of such treatment, the method comprising administering one or more biodegradable drug depots within a nasal or sinus cavity to treat, reduce or prevent such pain or inflammation, wherein the drug depot is in the form of a porous biodegradable material that comprises a therapeutically effective amount of an analgesic, anti-inflammatory agent or pharmaceutically acceptable salt thereof, releases a therapeutically effective amount of such analgesic, anti-inflammatory agent or pharmaceutically acceptable salt thereof over a period of at least 1 day, and has pores sized to prevent the depot from functioning as a scaffold for tissue growth. 
     
     
         13 . A method according to  claim 12 , wherein the analgesic comprises alfentanil, butorphanol, codeine, fentanyl, hydromorphone, levorphanol, meperidine, morphine, sufentanil, tramadol or a combination thereof, and the anti-inflammatory agent comprises clonidine, fluocinolone, dexamethasone, sulindac, sulfasalazine or a combination thereof. 
     
     
         14 . A method according to  claim 12 , wherein the drug depot releases 0.1 mg to 100 mg of the analgesic and the anti-inflammatory agent or pharmaceutically acceptable salt thereof every 24 to 48 hours to reduce, treat or prevent pain or inflammation over a period of 3 days to 2 weeks after the drug depot is administered within the nasal or sinus cavity. 
     
     
         15 . A method according to  claim 12 , wherein the drug depot comprises a polymer comprising poly(lactide-co-glycolide) (PLGA), polylactide (PLA), polyglycolide (PGA), D-lactide, D,L-lactide, L-lactide, D,L-lactide-e-caprolactone, poly(orthoester) (POE), D,L-lactide-glycolide-ε-caprolactone or a combination thereof. 
     
     
         16 . A method according to  claim 12 , wherein the drug depot comprises a polymer and the polymer comprises about 70% to about 90% of the total weight % of the drug depot. 
     
     
         17 . A method according to  claim 12 , wherein the drug depot releases (i) a bolus dose of the analgesic or pharmaceutically acceptable salt thereof within the nasal or sinus cavity over a period up to 3 days and (ii) an effective amount of the anti-inflammatory agent or pharmaceutically acceptable salt thereof over a period of up to 2 weeks. 
     
     
         18 . (canceled) 
     
     
         19 . A method according to  claim 12 , wherein the drug depot is in the form of a nasal packing matrix, wafer, film, strip, ribbon or patch. 
     
     
         20 . A method according to  claim 12 , wherein the drug depot is in the form of a sinus packing matrix, wafer, film, strip, ribbon or patch. 
     
     
         21 . A method according to  claim 12 , wherein the drug depot is in the form of a sinus packing sponge. 
     
     
         22 . A method according to  claim 12 , wherein the pores have a size less than 500 micrometers. 
     
     
         23 . A method according to  claim 12 , wherein the pores have a size less than 250 micrometers and prevent cells from entering the drug depot. 
     
     
         24 . A method according to  claim 12 , wherein the drug depot has multiple different layers. 
     
     
         25 . A method according to  claim 12 , wherein the drug depot comprises a polysaccharide. 
     
     
         26 . A method according to  claim 12 , wherein the drug depot comprises chitosan. 
     
     
         27 . A method according to  claim 12 , wherein the anti-inflammatory agent comprises a steroid. 
     
     
         28 . A method according to  claim 12 , wherein the anti-inflammatory agent comprises fluticasone propionate or mometasone furoate. 
     
     
         29 . A method according to  claim 12 , wherein the depot comprises a radiographic marker. 
     
     
         30 . A method according to  claim 12 , further comprising providing the drug depot in sterile packaging. 
     
     
         31 . A method according to  claim 12 , further comprising administering the depot using a delivery device. 
     
     
         32 . A method according to  claim 12 , further comprising administering the depot to a target tissue site using a gel that adheres or holds the depot in place on the target site.